SCHEMBL1746654

SCHEMBL1746654

O=C(O)CCc1ccc(OCc2ccc(C(=O)c3ccc(Cl)cc3)cc2)cc1

nearest known ligand 0.67

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 13/20 0.67
FFAR4 Q5NUL3 8/20 0.67
NR4A2 P43354 1/20 0.67
MAOB P27338 2/20 0.61
MAOA P21397 1/20 0.61
SRD5A2 P31213 2/20 0.59
ALDH1A1 P00352 1/20 0.55
HTT P42858 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
AKR1B1 P15121 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1744622 0.89 FFAR1 (0.80) FFAR1FFAR4SRD5A2ALDH1A1HTT
SCHEMBL8503301 0.85 NR4A2 (0.74) NR4A2MAOBMAOASRD5A2ALDH1A1
SCHEMBL1745366 0.85 MAOB (0.60) FFAR1NR4A2MAOBMAOASRD5A2
SCHEMBL8503299 0.84 SRD5A2 (0.77) NR4A2MAOBMAOASRD5A2ALDH1A1
SCHEMBL21991528 0.81 NR4A2 (0.67) FFAR1FFAR4NR4A2MAOBMAOA
Benzyloxyphenylpropanoic Acid SCHEMBL1134648 0.81 FFAR1 (1.00) FFAR1FFAR4AKR1B1
SCHEMBL1744939 0.81 FFAR1 (1.00) FFAR1FFAR4AKR1B1
SCHEMBL1369316 0.81 NR4A2 (1.00) NR4A2MAOBMAOASRD5A2SMN1; SMN2
SCHEMBL14130003 0.80 NR4A2 (0.66) NR4A2MAOBMAOASRD5A2ALDH1A1
SCHEMBL1745398 0.80 FFAR1 (0.59) FFAR1FFAR4NR4A2MAOBMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR FFAR1 33/4885FFAR4 44/4885NR4A2 96/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.